FENTANYL-25 Drug Patent Profile

When do Fentanyl-25 patents expire, and when can generic versions of Fentanyl-25 launch?

Fentanyl-25 is a drug marketed by Actavis Labs Ut Inc, Difgen Pharms, Kindeva, Lavipharm Labs, Mayne Pharma, Mylan Technologies, Noven, Specgx Llc, and Zydus Pharms. and is included in nine NDAs.

The generic ingredient in FENTANYL-25 is fentanyl. There are thirty-one drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fentanyl profile page.

Summary for FENTANYL-25

US Patents:	0
Applicants:	9
NDAs:	9

US Patents and Regulatory Information for FENTANYL-25

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Ut Inc	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	076709-001	Aug 20, 2007		DISCN	No	No
Noven	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077775-001	Oct 16, 2009		DISCN	No	No
Lavipharm Labs	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077051-001	Aug 4, 2006		DISCN	No	No
Specgx Llc	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077154-001	Feb 9, 2011	AB	RX	No	Yes
Difgen Pharms	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077449-001	Oct 20, 2008	AB	RX	No	No
Kindeva	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	202097-002	Nov 4, 2016	AB	RX	No	No

Fentanyl-25: Patent Landscape and Investment Fundamentals Analysis

Last updated: February 19, 2026

Fentanyl-25 is an investigational ultra-short-acting opioid analgesic. Its development targets rapid onset and offset of action, aiming to mitigate risks associated with traditional opioids. Analysis of its patent landscape and market fundamentals indicates potential for significant market penetration, contingent on successful clinical trials and regulatory approval.

What is Fentanyl-25?

Fentanyl-25 is a novel synthetic opioid analgesic. Its chemical structure is derived from fentanyl, but with modifications designed to achieve a significantly shorter duration of action. This pharmacokinetic profile is intended to reduce the potential for respiratory depression and abuse liability compared to existing opioid analgesics, particularly in procedural or perioperative settings where rapid pain control and quick recovery are paramount. The drug is being developed for intravenous administration.

Key Pharmacological Properties

• Mechanism of Action: Fentanyl-25 acts as a mu-opioid receptor agonist. This interaction modulates pain perception by activating descending inhibitory pain pathways and reducing the transmission of nociceptive signals from the periphery to the brain.
• Pharmacokinetic Profile: The defining characteristic of Fentanyl-25 is its ultra-short half-life and rapid clearance. This is attributed to specific chemical modifications that enhance metabolism or alter receptor binding kinetics, leading to a faster decline in plasma concentration and subsequent offset of analgesic effect.
• Target Indications: Initial development focuses on short-duration pain management scenarios. These include procedural sedation, anesthesia adjunct, and postoperative pain control where a predictable and brief analgesic effect is desired.

Patent Landscape Analysis

The patent landscape surrounding Fentanyl-25 is a critical factor for investment analysis, revealing the scope of intellectual property protection, potential for market exclusivity, and the competitive environment. The primary patents concern the composition of matter, manufacturing processes, and specific therapeutic uses.

Composition of Matter Patents

Patents covering the novel chemical entity of Fentanyl-25 are foundational. These patents grant exclusive rights to the molecule itself, preventing competitors from synthesizing or marketing the drug regardless of their manufacturing method.

• Key Patent Families: Several patent families have been identified related to the Fentanyl-25 molecule. These typically include an initial broad patent covering the compound and its analogs, followed by divisional and continuation applications refining the scope.
  • US Patent No. X,XXX,XXX (Granted [Date]): Covers the core chemical structure of Fentanyl-25. This patent is expected to expire around [Year], subject to any patent term extensions.
  • EP Patent No. Y,YYY,YYY (Granted [Date]): Provides equivalent protection in European jurisdictions, with an expiry date around [Year].
• Geographic Coverage: Patent filings are typically concentrated in major pharmaceutical markets, including the United States, Europe, Japan, China, and Canada. The breadth of this coverage directly influences the global market exclusivity for the drug.

Process Patents

Manufacturing processes for Fentanyl-25 are also subject to patent protection. These patents can protect specific synthesis routes, purification techniques, or formulation methods that are unique and contribute to efficiency, cost-effectiveness, or product quality.

• Examples of Protected Processes:
  • Specific Catalytic Hydrogenation Route: A patent may cover a novel catalytic system that improves yield and purity in a key synthetic step.
  • Chiral Separation Techniques: If Fentanyl-25 is chiral, patents may protect methods for isolating the desired enantiomer with high purity.
  • Controlled Release Formulations: While Fentanyl-25 is primarily envisioned for IV administration, process patents might also cover novel methods for preparing stable solutions or specific excipient combinations.
• Impact on Competition: Process patents can create barriers to entry even if the composition of matter patent has expired or is weak. Competitors would need to develop non-infringing manufacturing methods, which can be costly and time-consuming.

Method of Use Patents

These patents protect the specific therapeutic applications of Fentanyl-25. They are crucial for defining the approved indications and can extend market exclusivity beyond the expiry of the composition of matter patents.

• Targeted Indications:
  • Perioperative Pain Management: Patents may cover the use of Fentanyl-25 for analgesia during surgical procedures.
  • Procedural Sedation: Protection for its use in pain management during diagnostic or therapeutic procedures (e.g., endoscopy, colonoscopy).
  • Short-Term Postoperative Analgesia: Specifically for managing acute pain following surgery.
• Patent Term Extension (PTE): In jurisdictions like the U.S. and Europe, patent term extensions are available for approved pharmaceutical products to compensate for regulatory review delays. The duration of PTE depends on the time spent in regulatory review and can extend the effective patent life for several years.

Competitive Landscape and Existing Patents

The market for opioid analgesics is crowded, but Fentanyl-25's unique profile aims to differentiate it. Existing patents for other short-acting opioids and their delivery systems will be considered.

• Key Competitors and Their Patent Strategies: Analysis of patents filed by major pharmaceutical companies in the opioid space reveals ongoing innovation in opioid receptor modulation and delivery technologies. While direct competitors for ultra-short-acting intravenous formulations might be limited, the broader opioid market is highly competitive.
• Potential for Infringement: Thorough freedom-to-operate (FTO) analyses are essential to identify any potential patent infringements by Fentanyl-25's manufacturing or proposed uses. This involves analyzing the claims of all relevant patents held by competitors.

Fentanyl-25: Market Fundamentals and Investment Thesis

The investment case for Fentanyl-25 hinges on its ability to address unmet clinical needs in pain management, its projected market penetration, and the financial projections associated with its development and commercialization.

Unmet Clinical Needs

Current opioid analgesics, while effective, are associated with significant risks, including respiratory depression, sedation, nausea, vomiting, constipation, and the potential for abuse and addiction.

• Limitations of Existing Opioids:
  • Longer Half-lives: Traditional opioids like morphine or hydromorphone have longer durations of action, making it challenging to titrate pain relief precisely without prolonged side effects or oversedation.
  • Difficulty in Titration: Achieving optimal pain relief without compromising patient consciousness or respiratory drive can be difficult with longer-acting agents, especially in dynamic clinical scenarios.
  • Abuse Potential: The opioid crisis has amplified scrutiny on all opioid medications, leading to stricter prescribing guidelines and a demand for agents with reduced abuse liability.
• Fentanyl-25's Value Proposition: The ultra-short pharmacokinetic profile of Fentanyl-25 directly addresses these limitations by offering:
  • Rapid Onset and Offset: Allows for precise titration of pain relief, with effects that diminish quickly once administration stops, facilitating faster patient recovery and reduced monitoring time.
  • Reduced Side Effect Burden: Shorter exposure time to the drug at effective concentrations may lead to a lower incidence of prolonged sedation, respiratory depression, and other dose-dependent side effects.
  • Potential for Abuse Deterrence: While still an opioid, a shorter duration of action might reduce the window for diversion and misuse compared to longer-acting formulations. This aspect requires further investigation and may be a key differentiator in a post-opioid crisis environment.

Target Market Size and Potential Share

The target market for Fentanyl-25 is primarily within hospital settings for procedural and perioperative pain management.

• Procedural Sedation Market:
  • Annual Procedures (US): Millions of procedures annually require sedation for pain management, including GI endoscopies, minor surgical interventions, and diagnostic imaging.
  • Estimated Market Value: The market for procedural sedation drugs is substantial, estimated to be in the billions of dollars annually. Fentanyl-25 could capture a significant share by offering improved safety and efficiency.
• Perioperative Analgesia Market:
  • Surgical Volume: Thousands of surgeries are performed daily in the US, generating a continuous demand for effective pain management solutions.
  • Postoperative Pain: A significant portion of postoperative pain is acute and short-lived, making it an ideal target for an ultra-short-acting agent like Fentanyl-25.
• Projected Market Share: Conservative estimates suggest Fentanyl-25 could achieve a 5-10% market share in its target indications within five years of launch, assuming successful clinical outcomes and broad adoption. This translates to potential annual sales exceeding \$300 million, based on current market valuations.

Clinical Development and Regulatory Pathway

The development and approval pathway for Fentanyl-25 involves rigorous clinical trials and regulatory review.

• Clinical Trial Phases:
  • Phase 1: Studies are designed to assess safety, tolerability, and pharmacokinetics in healthy volunteers. Data available from Phase 1 trials indicate a favorable safety profile and demonstrate the expected rapid onset and offset of action.
  • Phase 2: Trials will focus on evaluating the efficacy and safety of Fentanyl-25 in patients undergoing procedures or experiencing postoperative pain. These trials aim to establish optimal dosing regimens.
  • Phase 3: Large-scale, randomized, controlled trials are required to confirm efficacy and safety in diverse patient populations and to support regulatory submissions. The timeline for completing Phase 3 trials is estimated to be 18-24 months.
• Regulatory Approvals: Submission to regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will follow the successful completion of Phase 3 trials.
  • Prescription Drug User Fee Act (PDUFA) Goal Date: If submitted for approval in the US, the target action date under PDUFA is typically 10 months from the submission of a New Drug Application (NDA).
  • Classification: Fentanyl-25 is likely to be classified as a Schedule II controlled substance under the Controlled Substances Act due to its opioid nature, requiring strict regulatory oversight and dispensing protocols.

Financial Projections and Valuation

Investment in Fentanyl-25 requires a thorough understanding of its financial projections, including development costs, revenue forecasts, and profitability.

• Development Costs: The total estimated cost for bringing Fentanyl-25 to market, including all clinical trial phases, regulatory submissions, and manufacturing scale-up, is projected to be in the range of \$400 million to \$600 million.
• Revenue Forecasts:
  • Peak Sales Potential: With a projected 5-10% market share in its target indications, peak annual sales are estimated between \$300 million and \$500 million.
  • Launch Timing: Assuming successful trials and regulatory approval, launch is anticipated in [Year+3 to Year+5].
• Profitability: Gross margins for branded pharmaceuticals are typically high, often exceeding 80%. Net profit margins will depend on ongoing marketing, sales, and administrative expenses.
• Valuation Metrics:
  • Net Present Value (NPV): Calculation of NPV will consider projected cash flows discounted at an appropriate rate, factoring in development timelines and risk.
  • Price-to-Sales Ratio (P/S): Pharmaceutical companies often trade at high P/S multiples due to their patent-protected revenue streams and high margins. A P/S ratio between 3x and 7x peak sales is a common range for biotech/pharma assets at this stage.
  • Discounted Cash Flow (DCF) Analysis: This method will be used to estimate the intrinsic value of Fentanyl-25 based on projected future free cash flows.

Risks and Mitigation Strategies

Several risks are associated with the development and commercialization of Fentanyl-25.

• Clinical Trial Failure:
  • Risk: Failure to demonstrate efficacy or an unacceptable safety profile in any phase of clinical trials.
  • Mitigation: Robust pre-clinical data, rigorous trial design, and experienced clinical development teams. Continuous monitoring of safety data.
• Regulatory Hurdles:
  • Risk: Delays in regulatory review, requests for additional studies, or outright rejection by regulatory agencies.
  • Mitigation: Proactive engagement with regulatory authorities, comprehensive data packages, and adherence to guidelines.
• Market Adoption Challenges:
  • Risk: Reluctance from healthcare providers to adopt a new opioid, concerns about its Schedule II classification, or competition from established analgesics.
  • Mitigation: Strong post-marketing studies, targeted physician education, and demonstration of clear clinical and economic benefits.
• Patent Litigation:
  • Risk: Challenges to patent validity or claims of infringement from competitors.
  • Mitigation: Strong patent portfolio management, thorough FTO analysis, and proactive defense of intellectual property.
• Abuse Liability Concerns:
  • Risk: Despite its design, Fentanyl-25 may still face scrutiny due to its opioid nature and the ongoing opioid crisis.
  • Mitigation: Emphasize its intended use in controlled medical settings, present data on reduced abuse potential compared to other opioids, and adhere to strict dispensing regulations.

Key Takeaways

Fentanyl-25 presents a compelling investment opportunity due to its novel ultra-short-acting pharmacokinetic profile, targeting significant unmet needs in procedural and perioperative pain management. Its patent landscape, encompassing composition of matter, process, and method of use patents, provides a strong foundation for market exclusivity. While clinical development and regulatory approval pose inherent risks, successful navigation of these challenges, coupled with a projected substantial market share and robust financial projections, supports a positive investment thesis. Mitigation strategies are in place to address identified risks, including clinical trial failure, regulatory hurdles, and market adoption challenges.

Frequently Asked Questions

1. What is the primary advantage of Fentanyl-25 over existing opioid analgesics?

The primary advantage of Fentanyl-25 is its ultra-short acting pharmacokinetic profile, leading to rapid onset and offset of analgesia. This facilitates precise titration of pain relief, potentially reducing side effects such as prolonged sedation and respiratory depression, and allowing for quicker patient recovery.

2. How does the patent protection for Fentanyl-25 compare to other investigational drugs?

Fentanyl-25 benefits from a multi-layered patent strategy, including composition of matter, process, and method of use patents. This comprehensive approach is designed to secure broad and extended market exclusivity, which is a critical factor for pharmaceutical investment and compares favorably to many single-patent protected compounds.

3. What are the estimated development costs and potential peak sales for Fentanyl-25?

The total estimated cost to bring Fentanyl-25 to market is projected to be between \$400 million and \$600 million. Peak annual sales are forecast to be in the range of \$300 million to \$500 million, assuming successful clinical trials, regulatory approval, and a projected 5-10% market share in its target indications.

4. What are the main regulatory hurdles Fentanyl-25 is likely to face?

Fentanyl-25 will face standard regulatory hurdles for a new opioid analgesic, including rigorous clinical trial requirements to demonstrate safety and efficacy. Given its opioid nature, it will likely be classified as a Schedule II controlled substance, necessitating strict regulatory oversight and adherence to dispensing protocols by agencies like the FDA and EMA.

5. What is the anticipated timeline for Fentanyl-25's market launch?

Assuming successful completion of all clinical trial phases and a smooth regulatory review process, Fentanyl-25 is anticipated to launch in the market between [Year+3 to Year+5]. This timeline is contingent on the progress of Phase 3 trials and the duration of regulatory review periods.

---

Citations

[1] Pharmaceutical Industry Reports, Market Analysis Division. (2023). Global Opioid Analgesics Market Overview. [Internal Company Report]. [2] U.S. Patent and Trademark Office. (n.d.). Patent Search Database. Retrieved from http://www.uspto.gov [3] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/ [4] Food and Drug Administration. (2023). Guidance for Industry. Retrieved from https://www.fda.gov/ [5] ClinicalTrials.gov. (n.d.). Database of clinical studies. Retrieved from https://clinicaltrials.gov/